* Allelix Biopharmaceuticals Inc., of Mississauga, Ontario, received a notice of allowance for a patent covering the composition and medical uses of the company's ALX-0600 and related gastrointestinal drug candidate compounds. ALX-0600 is an analog of the naturally occurring peptide glucagon-like peptide 2.
* AmCell Corp., of Sunnyvale, Calif., has rights to a patent issued to Miltenyi Biotec GmbH, of Bergisch Gladbach, Germany. The patent, No. 5,786,161 covers isolation and characterization of allergen-binding cells for diagnosis of hypersensitivity.
* Anergen Inc., of Redwood City, Calif., received patent No. 5,763,585, covering manufacturing methods for drugs based on the company's AnergiX technology, which combines disease specific auto-antigenic peptides with disease-associated major histocompatibility derived proteins, in a complex that is designed to inactivate T cells.
* Aphton Corp., of Miami, received patent No. 5,785,970 for gastrin-neutralizing treatments for gastrointestinal disorders. Included are applications of the company's Gastrimmune, designed to treat, among other things, various cancers, equine stress ulcers, and gastro-esophageal reflux disease.
* Aurora Biosciences Corp., of San Diego, received patent No. 5,777,079 for certain fluorescent proteins, including brightly colored mutants of green fluorescent protein (GFP). GFPs can be used in screening, genomic and toxicology programs based on gene expression.
* Lexicon Genetics Inc., of The Woodlands, Texas, has exclusive rights to a new patent — No. 5,789,215 — covering methods for using isogenic DNA technology to modify the genomes from multicellular animals. The patent is assigned to GenPharm International Inc., a wholly owned subsidiary of Medarex Inc., of Annandale, N.J.
* Matrix Pharmaceutical Inc., of Fremont, Calif., was reissued a patent covering aqueous fibrillar collagen and/or fibrinogen composition containing cytotoxic drugs or proliferation inhibitors. The patent, No. Re35748, also covers the use of such compositions in treating neopastic or hyperproliferative lesions.
* MediChem Research Inc., of Lemont, Ill., received patent No. 5,773,462 for preparation of its robustaflavone antiviral agent, as well as seven other biflavanoid compounds. The patent for "Biflavonoids and Derivatives Thereof as Antiviral Agents" includes an improved method for obtaining substantially pure robustaflavone from plant material.
* Molecular Targeting Technology Inc., of Malvern, Pa., has worldwide rights to a patent issued to Northeastern University, of Boston. The patent covers a gene therapy that prevents cell death by "plugging" and "sealing" cell membrane lesions.
* Myriad Genetics Inc., of Salt Lake City, received patent No. 5,789,206, entitled "5' Hybrid Capture Rapid Amplification of cDNA Ends," which covers aspects of the company's 5-Prime RACE technology for finding the ends of genes.
* Neurocrine Biosciences Inc., of San Diego, received patent No. 5,796,203 for nucleic acid sequence encoding CRF(2) receptors. The company also has exclusively licensed two patents from the Salk Institute: No. 5,728,545, for the nucleic acid sequence encoding the CRF receptor; and No. 5,464,757, for nucleic acid molecules encoding the CRF binding protein. The company and partner Janssen Pharmaceutica NV are completing Phase I clinical trials of a CRF receptor antagonist. Janssen is a wholly owned subsidiary of Johnson & Johnson, of New Brunswick, N.J.